Subspecies distribution and macrolide and fluoroquinolone resistance genetics of Mycobacterium abscessus in Korea

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 1, 2016, Pages 109-114

  Kim, J ^a   Sung, H ^a   Park, J S ^a   Choi, S H ^a   Shim, T S ^a   Kim, M N ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Ciprofloxacin; Clarithromycin; M. abscessus subsp. abscessus; M. abscessus subsp. bolletii; Mycobacterium abscessus

Indexed keywords

AMIKACIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DOXYCYCLINE; IMIPENEM; LINEZOLID; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; ERM(41) GENE; GENE MUTATION; GRYA GENE; GYRB GENE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM ABSCESSUS SUBSP. ABSCESSUS; MYCOBACTERIUM MASSILIENSE; NONHUMAN; PRIORITY JOURNAL; RRL GENE; SOUTH KOREA; SPECIES DISTRIBUTION; SUBSPECIES; SUBSPECIES DISTRIBUTION; CLASSIFICATION; DRUG EFFECTS; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; PHYLOGENY; POLYMERASE CHAIN REACTION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; PHYLOGENY; POLYMERASE CHAIN REACTION; REPUBLIC OF KOREA;

EID: 84952007761     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.15.0068     Document Type: Article

References (32)

1. Koh W J, Kwon O J, Lee K S. Diagnosis and treatment of non-tuberculous mycobacterial pulmonary diseases: a Korean perspective. J Korean Med Sci 2005; 20: 913-925.
2. Park Y S, Lee C H, Lee S M, et al. Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea. Int J Tuberc Lung Dis 2010; 14: 1069-1071.
3. Adekambi T, Berger P, Raoult D, Drancourt, M. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 2006; 56: 133-143.
4. Adekambi T, Reynaud-Gaubert M, Greub G, et al. Amoebal coculture of 'Mycobacterium massiliense' sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol 2004; 42: 5493-5501.
5. Leao S C, Tortoli E, Euzeby J P, Garcia M J. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011; 61: 2311-2313.
6. Griffith D E, Girard W M, Wallace R J. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147: 1271-1278.
7. Mushatt D M, Witzig R S. Successful treatment of Mycobacterium abscessus infections with multidrug regimens containing clarithromycin. Clin Infect Dis 1995; 20: 1441-1442.
8. Bastian S, Veziris N, Roux A L, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55: 775-781.
9. Maurer F P, Castelberg C, Quiblier C, Böttger EC, Somoskö vi A. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. J Antimicrob Chemother 2014; 69: 1559-1563.
10. Wallace R J, Meier A, Brown B A, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996; 40: 1676-1681.
11. Nash K A, Brown-Elliott B A, Wallace R J Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53: 1367-1376.
12. Cheng A F, Yew W W, Chan E W, et al. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004; 48: 596-601.
13. Revel V, Cambau E, Jarlier V, Sougakoff W. Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones. Antimicrob Agents Chemother 1994; 38: 1991-1996.
14. Goswitz J J, Willard K E, Fasching C E, Peterson L R. Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing. Antimicrob Agents Chemother 1992; 36: 1166-1169.
15. Oram M, Fisher L M. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother 1991; 35: 387-389.
16. Wang Y, Huang W M, Taylor D E. Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations. Antimicrob Agents Chemother 1993; 37: 457-463.
17. Telenti A, Marchesi F, Balz M, et al. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol 1993; 31: 175-178.
18. Griffith D E, Aksamit T, Brown-Elliott B A, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of non-tuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
19. Kim J, Park J S, Jeong Y S, Kim D Y, Sung H, Kim M N. Mycobacterium massiliense bacteremia as a consequence of M. massiliense pneumonia in a patient with acute lymphoblastic leukemia. J Clin Microbiol 2014; 52: 2235-2238.
20. nd ed. Wayne, PA, USA: CLSI, 2011.
21. Guillemin I, Cambau E, Jarlier V. Sequences of conserved region in the A subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis and implication for intrinsic susceptibility to quinolones. Antimicrob Agents Chemother 1995; 39: 2145-2149.
22. Dauendorffer J N, Guillemin I, Aubry A, et al. Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes. J Clin Microbiol 2003; 41: 1311-1315.
23. Guillemin I, Jarlier V, Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother 1998; 42: 2084-2088.
24. Kim H Y, KookY, Yun Y J, et al. Proportions of Mycobacterium massiliense and Mycobacterium bolletii strains among Korean Mycobacterium chelonae-Mycobacterium abscessus group isolates. J Clin Microbiol 2008; 46: 3384-3390.
25. Koh W J, Jeon K, Lee N Y, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011; 183: 405-410.
26. Zelazny A M, Root J M, Shea Y R, et al. Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J Clin Microbiol 2009; 47: 1985-1995.
27. van Ingen J, de Zwaan R, Dekhuijzen R P, Boeree M J, van Soolingen D. Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients. J Infect 2009; 59: 324-331.
28. Roux A L, Catherinot E, Ripoll F, et al. Multicenter study of prevalence of non-tuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol 2009; 47: 4124-4128.
29. Park S, Kim S, Park E M, et al. In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea. J Korean Med Sci 2008; 23: 49-52.
30. de Moura V C, daSilva MG, GomesK M, et al. Phenotypic and molecular characterization of quinolone resistance in Mycobacterium abscessus subsp. bolletii recovered from postsurgical infections. J Med Microbiol 2012; 61: 115-125.
31. Monego F, Duarte R S, Biondo A W. gyrA and gyrB gene mutation in ciprofloxacin-resistant Mycobacterium massiliense clinical isolates from Southern Brazil. Microb Drug Resist 2012; 18: 1-6.
32. Woods G L, Bergmann J S, Witebsky F G, et al. Multisite reproducibility of E-test for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. J Clin Microbiol 2000; 38: 656-661.